Decreased susceptibility to copper‐induced oxidation of rat‐lipoproteins after fibrate treatment: influence of fatty acid composition
- 1 March 1996
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 117 (6) , 1155-1162
- https://doi.org/10.1111/j.1476-5381.1996.tb16710.x
Abstract
1. The effect of clofibrate (CFB), bezafibrate (BFB), and gemfibrozil (GFB) on plasma lipoprotein (VLDL and LDL) concentration, composition and resistance to copper-induced oxidation has been studied in male Sprague-Dawley rats after a 15 day treatment. 2. Plasma triglyceride levels were reduced by CFB (41%) and BFB (39%). This effect was related to a significant reduction (67% for CFB and 56% for BFB) in the amount of circulating VLDL-protein. 3. Plasma total cholesterol was reduced by 28% and 45% in CFB- and BFB-treated animals, respectively, mainly by modification of the cholesteryl ester fraction. In contrast, GFB significantly increased total cholesterol (27%). No modification in the LDL protein or lipid content was introduced by fibrates, although GFB decreased the proportion of LDL-triglycerides, at the expense of an increase in total cholesterol. 4. The fatty acid species carried by VLDL and LDL were affected after fibrate treatment. In general, both particles showed an increase in monounsaturated fatty acids (MUFA) (18:1) and a decrease in polyunsaturated fatty acids (PUFA) species (18:2 n-6, 20:4 n-6, 18:3 n-3, 20:5 n-3). As a consequence, the ratio of PUFA/(SFA+MUFA) for the whole lipoproteins was markedly reduced. 5. The degree of copper-induced VLDL- and LDL-oxidation was assessed by means of the analysis of lysine content, thiobarbituric acid reactive substances (TBARS) production and conjugated dienes formation. Lipoproteins obtained from fibrate-treated rats were more resistant to the oxidative challenge. For each lipoprotein, BFB was the most effective drug, followed by CFB and GFB. 6. The observed antioxidant effect can be ascribed to two independent phenomena produced by fibrates: the reduction of the amount of substrate for the oxidation process due to their hypolipidemic activity, and the alteration in the type of fatty acids transported by the lipoproteins towards an enrichment in species resistant to the oxidation process. 7. As similar lipoprotein fatty acid changes have been reported after fibrate treatment in human subjects, an antioxidant effect of fibrates in human therapy, independent of their well known hypolipidaemic activity, should be expected.Keywords
This publication has 33 references indexed in Scilit:
- Animal models of human lipid metabolismProgress in Lipid Research, 1993
- Tolerability of fibric acids. comparative data and biochemical basesPharmacological Research, 1992
- Structure and functional properties of lipoprotein lipaseBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1992
- Lipoprotein Assembly and Secretion by HepatocytesAnnual Review of Nutrition, 1990
- The use of newly synthesized phospholipids for assembly into secreted hepatic lipoproteinsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1989
- The Effect of Peroxisome Prouferators on Microsomal. Peroxisomal, and Mitochondrial Enzyme Activities in the Liver and KidneyDrug Metabolism Reviews, 1987
- Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid estersAtherosclerosis, 1980
- Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with diet, clofibrate and niceritrol Reduction of the proportion of linoleate by clofibrate but not by niceritrolAtherosclerosis, 1980
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959